Drug Development Service Targeting TAM Depletion

The Necessary of TAM Depletion

In the backdrop of cancer, tumor-associated macrophages (TAMs) typically play a crucial role in promoting tumor development and spread within the tumor microenvironment (TME). In general, the increased number of TAMs is linked with a poor clinical prognosis. Evidence shows that higher levels of M1-like TAMs are associated with a more favorable prognosis, while increased numbers of M2-like TAMs or a decrease in the ratio of lymphocytes to monocytes are indicative of poorer outcomes. Therefore, the selective depletion of M2-like TAMs during chemotherapy may be a promising strategy to inhibit cancer progression effectively.

Fig.1 Immunotherapies targeting TAMs.¹

Existing Strategies for Depletion of TAMs

Anti-CSF-1R: CSF-1/CSF-1R is crucial for the growth of the mononuclear phagocyte system and the advancement of tumors. And, blocking the targets causes an accumulation of TAMs to undergo apoptosis.
Trabectedin: Trabectedin triggers caspase-8-dependent apoptosis in mononuclear phagocytes, which leads to the targeted reduction of monocytes or macrophages in both blood and tumors.
Bisphosphonates: Bisphosphonates have the potential to induce tumor cell death and enhance immune surveillance by specifically targeting macrophages. This targeting mechanism helps prevent tumor cell invasion, reduces angiogenesis, and can also work synergistically with other anti-neoplastic medications.

Fig.2 Existing strategies targeting TAMs.²

Our Drug Development Service Targeting TAM Depletion

Creative Biolabs developed a cost-effective drug development service targeting TAM depletion to promote drug development in cancer therapy. In this service, we design innovative drugs based on inhibiting M2-TAM production or promoting M2-TAM apoptosis. We target different molecules to achieve TAM depletion in cancer therapy in terms of different pathways. In addition, we also provide diverse types of drug development services to meet global customers' needs. Together with our experienced experts, we have great confidence in delivering desirable results at a rapid time.

Specifically, we provide several targets based on the two principles as following in our drug development service targeting TAM depletion:

Targets for inhibiting M2-TAM polarization and downregulating M2-TAM production:

Fig.3 Targets for inhibiting M2-TAM polarization and downregulating M2-TAM production. (Creative Biolabs Original)

Targets for inhibiting M2-TAM recognition and promoting M2-TAM apoptotic:

Fig.4 Targets for inhibiting M2-TAM recognition and promoting M2-TAM apoptotic. (Creative Biolabs Original)

Simultaneously, we also provide multiple drug types development services to support global customers' diverse projects:

Fig.5 Multiple drug types development services. (Creative Biolabs Original)

What Will You Gain

Multiple types of targets to choose from aid in our drug development service targeting TAM depletion.
Diverse drug development services to satisfy global customers' diverse needs.
Shorter development timelines assist in our drug development service targeting TAM depletion.
Unparalleled expertise and experience guarantee our drug development service targeting TAM depletion.
Comprehensive customized services strengthen our drug development service targeting TAM depletion.

Partner with Creative Biolabs

Fig.6 Contact flowchart. (Creative Biolabs Original)

Here Creative Biolabs provides an inquiry mode for your convenience to contact us if you want to know more details about our drug development service targeting TAM depletion.

References

Petty, Amy J., et al. "Targeting tumor-associated macrophages in cancer immunotherapy." Cancers 13.21 (2021): 5318.
Hourani, Tetiana, et al. "Tumor-associated macrophages: Origin, recruitment, phenotypic diversity, and targeting." Frontiers in Oncology 11 (2021): 788365.